Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Pharmacoepidemiology and Drug Safety2004Vol. 13(7), pp. 417–426
Citations Over TimeTop 1% of 2004 papers
Abstract
Rhabdomyolysis is a rare, serious side effect of statin monotherapy and of statin-fibrate combination therapy. Clinicians need to remain cognizant of this potential adverse event and discuss signs and symptoms of muscle toxicity with patients in order improve the benefits-to-risks of treating dyslipidemia with statins.
Related Papers
- → Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1(2007)63 cited
- → A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus(2002)20 cited
- Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.(1989)
- → Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolemia(1991)32 cited
- [Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].(1995)